Abstract:Objective:To investigate the antitumor activity and the mechanism of cytokine-induced killer (CIK) cells combined with bevacizumab against hepatocellular carcinoma HepG2 cells in vitro and in vivo.Methods:Peripheral blood mononuclear cells (PBMCs) from healthy blood donors were isolated and cultured in the presence of different cytokines to promote the maturation of CIK cells;and the immune phenotypes of CIK cells were analyzed by flow cytometry.The inhibitory effect on HepG2 cells of CIK cells combining with or without bevacizumab were analyzed by CCK-8 assay.Cell migration and invasion of HepG2 cells were detected by scratch assay and transwell assay.The phosphorylation levels of Erk/Akt signaling pathway related proteins were detected by Western blotting.HepG2 cell xenograft tumor model was established in nude mice.Tumor bearing mice were divided into normal saline control group,CIK group,bevacizumab group and CIK + bevacizumab group.On the 28th day after drug administration,the mice were sacrificed and tumors were isolated.Immunohistochemical staining was used to analyze the expressions of CD31 and Ki67.Results:Human PBMCs were stimulated for 14 days,and the CIK cell phenotype analysis showed that the amplification of CD3 + CD56 + CIK cells reached (36.33 ± 2.58) ％.The inhibition rate of CIK cells combined with bevacizumab was significantly enhanced by comparing with CIK/bevacizumab alone groups (all P ＜ 0.05).CIK cells combined with bevacizumab showed a more intensive inhibition on cell migration([75.6 ±9.53] vs [304.8 ±45.73],[359.8 ±38.10],P ＜0.01) and invasion ([29.35 ± 8.14] ％ vs [55.07 ± 6.27] ％,[60.50 ± 9.73] ％,P ＜ 0.05] by comparing with those two single treatment groups;CIK cell treatment,bevacizumab treatment and the combined treatment could all decrease the phosphorylation level of Erk and Akt;the combined treatment significantly inhibited the tumor growth,mean vessel density (MVD) and Ki67 expression,which had statistical significance when compared with the other groups (P ＜ 0.05).Conclusion:The current study suggested that CIK cells combined with bevacizumab inhibited HepG2 ceils proliferation,invasion and migration both in vitro and in vivo,which significantly precede the treatment efficacy of single treatment groups.

Cytokine-induced Killer Cells Combined with Dendritic Cells Inhibited Liver Cancer Cells.

Cytokine-Induced Killer (cik) Cell Therapy for Patients with Hepatocellular Carcinoma: Efficacy and Safety

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

Co-culture of Dendritic Cells and Cytokine-Induced Killer Cells Effectively Suppresses Liver Cancer Stem Cell Growth by Inhibiting Pathways in the Immune System

Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.

Study on Anti-mouse Hepatocellular Carcinoma Effect of Cytokine-induced Kill Cells Activated by Dendritic Cells Transfected with Mouse Hepatocellular Carcinoma Total RNA in Vitro

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.

Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma.

The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma: a Meta-Analysis.

[Killing Activity in DC and CIK Co-Culture Against Hepatocarcinoma Cells].

Gemcitabine Treatment Enhanced the Anti-Tumor Effect of Cytokine Induced Killer Cells by Depletion of CD4+CD25bri Regulatory T Cells

The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for

Short-term curative efficacy of cytokine-induced killer cells combined micro-invasive treatments on hepatocellular carcinoma]

Immunotherapy of Patient with Hepatocellular Carcinoma Using Cytotoxic T Lymphocytes Ex Vivo Activated with Tumor Antigen-Pulsed Dendritic Cells

Clinical Effect of DC-CIK Cellular Immunity Combined with Apatinib in the Treatment of Liver Cancer

Anti-tumor activity of cytokine-induced killer cells combined with bevacizumab against hepatocellular carcinoma HepG2 cells in vitro and in vivo

Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo]

Autologous Transplantation of Cytokine-Induced Killer Cells As an Adjuvant Therapy for Hepatocellular Carcinoma in Asia: an Update Meta-Analysis and Systematic Review.

[Cytokine-Induced Killer Cell Fusion to Lower Recurrence of Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization Sequentially Combined with Radiofrequency Ablation: a Randomized Trial].

Induction of Specific Cytolytic T Lymphocytes Using Fusions of Hepatocellular Carcinoma (HCC) Patient-Derived Dendritic Cells and Allogeneic HCC Cell Line.

One Single Site Clinical Study: to Evaluate the Safety and Efficacy of Immunotherapy with Autologous Dendritic Cells, Cytokine-Induced Killer Cells in Primary Hepatocellular Carcinoma Patients